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ABSTRACT
The discovery of RNA interference (RNAi) gave rise
to the development of new nucleic acid-based tech-
nologies as powerful investigational tools and po-
tential therapeutics. Mechanistic key details of RNAi
in humans need to be deciphered yet, before such
approaches take root in biomedicine and molecular
therapy.
We developed and validated an in silico-based
model of siRNA-mediated RNAi in human cells in or-
der to link in vitro-derived pre-steady state kinetic
data with a quantitative and time-resolved under-
standing of RNAi on the cellular level. The obser-
vation that product release by Argonaute 2 is accel-
erated in the presence of an excess of target RNA in
vitro inspired us to suggest an associative mecha-
nism for the RNA slicer reaction where incoming tar-
get mRNAs actively promote dissociation of cleaved
mRNA fragments. This novel associative model is
compatible with high multiple turnover rates of RNAi-
based gene silencing in living cells and accounts
for target mRNA concentration-dependent enhance-
ment of the RNAi machinery.
INTRODUCTION
In mammalians, RNA interference (RNAi) is a vital post-
transcriptional gene silencing mechanism controlling devel-
opment and basic cellular processes such as cell growth, het-
erochromatin formation and tissue differentiation (1). Its
dysfunction is linked to cancer, cardiovascular disease and
other degenerative disorders (2–4). Since early on, there has
been great interest in RNAi (5–10), not least because of its
potential application in biomedicine andmolecular therapy.
Novel classes of oligonucleotides, i.e. small interferingRNA
(siRNA), are becoming powerful investigational tools and
potential therapeutics that allow to selectively turning off
genes in living organisms via the RNAi pathway (11). Espe-
cially promising is its high potential against heretofore un-
druggable targets. However, before RNAi-based drugs fully
reach the market, many mechanistic details of the complex
system have to be deciphered and quantified to yet tackle
challenges like increasing the efficacy of artificial siRNA,
pinpointing delivery or reducing harmful off-target effects
(12).
The main effector of RNAi is a ribonucleoprotein com-
plex known as RNA-induced silencing complex (RISC)
(13). Minimally, it consists of an Argonaute-family protein
and a short (19–21 nt) single-stranded (ss) RNA (14). The
origin of the short ssRNA is either endogenous double-
stranded (ds) miRNA (15,16) or siRNA duplex from ex-
ogenous sources (synthetic or infectious) (17). Initially, the
short RNA duplex with two nucleotides (nt) overhang at
each 3′-end and a phosphate group at each 5′-end (14,18)
binds to RISC. For RISC activation, the so-called pas-
senger strand needs to be removed, while the complemen-
tary guide strand is loaded onto Ago2. The Ago2-bound
guide strand recognizes the target gene’s mRNA with high
specificity via base-pairing. In case of siRNA, cleavage of
the captured mRNA is induced by the endonuclease Ago2,
the key component of RISC (19–21). Eventually, multiple
turnover of target recognition and degradation reduces the
cellular level of the given target mRNA (22–24).
Though, overall the mechanism of RNAi is reasonably
well understood, RISC remains a complex molecular ma-
chinery, embedded in an intricate intracellular networkwith
many yet unknown molecular players (25–30). In an at-
tempt to overcome this inherent experimental limitation, re-
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search in the field of RNAi has been complemented by theo-
retical biology. In the past, quantitative modelling of RNAi
has been performed using worms and plants as experimen-
tal system (31,32). Other studies focused on the miRNA
pathway (33–35). While siRNA-mediated RNAi was exten-
sively modelled by Bartlett et al. (36–38) and Cuccato et al.
(39), it was Larsson et al. (40), who shed light on the ef-
fect of target mRNA turnover rates on RNAi and, to our
knowledge, were the first to touch upon the influence of tar-
get abundance on RNAi efficacy.
Several X-ray crystallographic studies on bacterial and
eukaryotic proteins provided valuable conclusive insights
concerning crucial steps during the enzymatic cycle (41–
47). In combining these data with own biochemical studies,
we recently presented a comprehensive minimal mechanis-
tic model describing fundamental steps during RNAi (48).
The model defines hAgo2-mediated target mRNA binding
and cleavage, dissecting binary as well as ternary complex
formation and target mRNA cleavage into individual sub-
steps. Thus, it provides in-depth insights into the compli-
cated interplay of hAgo2with small RNAs and correspond-
ing target molecules.
In the present study, we combined these in vitro data with
quantitative data derived from cell culture experiments.
We developed a computational model, which is capable to
quantitatively predict important parameters of the RNAi
process in living mammalian cells and to unravel mechanis-
tic details of the underlying machinery. Cell culture exper-
iments suggest the RNAi machinery adapts to large vari-
ations in target mRNA levels, independent of siRNA or
Ago2 concentrations. These experimental findings cannot
be explained by the common literature view ofRNAi, which
may be described by a dissociative process, where the de-
parting ligands (here, cleaved RNA fragments) leave the
complex in a slow step with positive entropy of activa-
tion, before the next incoming ligand (i.e. uncleaved tar-
get mRNA) can enter. In vitro, the release of target RNA
from Ago2 is accelerated in the presence of an excess of
free target RNA (48). This inspired us to suggest an as-
sociative mechanism of target strand recognition by Ago2,
which involves binding of the next incoming target mRNA
to hAgo2 before dissociation of the cleaved mRNA frag-
ments. Here, the departing ligand is not any longer the
rate-limiting step. This new associative model, parameter-
ized with abovementioned pre-steady state kinetic rate con-
stants, is compatible with high multiple turnover rates of
RNAi-based gene silencing in living cells and accounts for
target mRNA concentration-dependent acceleration of the
RNAi machinery.
This alternative view likely might have an impact on the
selection of siRNA-based therapeutics, as the associative
model suggests that the efficacy of a siRNA or miRNA de-
pends on the expression level of its target mRNA in a way
that high target levels allow for better inhibitory effects.
MATERIALS AND METHODS
Cell lines, cell culture and LipofectamineTM 2000 (LF2000)-
mediated siRNA transfection
HeLa-TetOff (HTO; BD Biosciences, Heidelberg, Ger-
many) and HeLa-TetOff Luc (HTOL; stably transfected
with firefly luciferase) (49) cells were cultured in Dulbecco’s
Modified Eagle Medium with 4500 mg/l glucose. All media
were supplemented with 10% foetal calf serum (FCS) and
were purchased from Invitrogen. Cells were cultured as ex-
ponentially growing subconfluent monolayers in a humidi-
fied atmosphere containing 5% CO2.
Twenty four hours prior to transfection, cells were seeded
into 12 or 96-well plates (Greiner, Frickenhausen, Ger-
many). Cell numbers were chosen to finally reach 80–90%
confluency at the time of transfection. LF2000/siRNA
complexes were allowed to form in OptiMEM (Life Tech-
nologies) according to the manufacturer’s protocol with
a final concentration of 5–10 g/ml LF2000. Routinely,
the cell culture supernatant was discarded and replaced by
medium supplemented with 10% FCS 4 h after the start of
transfection. All information concerning incubation times
given in the manuscript refer to the time from the beginning
of the transfection procedure.
Determination of luciferase activity
Luciferase activity was quantified 24 h after transfection,
subsequent to the determination of cell viability by a fluo-
rescein diacetate (FDA, Sigma-Aldrich, Deisenhofen, Ger-
many) assay (49). Luminescence was measured in a mi-
croplate reader (Fluoroskan Ascent FL, Thermo Labsys-
tems, Dreieich, Germany) using 50–100 l of a buffer con-
taining 28mMTricine (pH 7.8), 500Madenosine triphos-
phate, 250 M coenzyme A, 250 M D-luciferin, 33 mM
DTT, 200 M EDTA, 15 mM MgSO4, 1.5% (v/v) Triton
X-100 and 5% (v/v) glycerol (all reagents purchased from
Sigma-Aldrich). The luminescence was normalized to cell
viability to account for cell loss due to cytotoxicity or wash-
ing procedures. For the determination of IC50 values RNAi-
mediated downregulation of the luciferase activity was plot-
ted as the percentage of active siR206 (50) versus inactive
siINV (49) and the experimental data were fitted with an
‘IC50 full 4 param’ equation using the GraFit5 software
(Erithacus Software, Surrey, UK).
Quantification of intracellular siRNA concentration via liq-
uid hybridisation assay
Transfections were carried out as described above in a 12-
well format. Cells were detached by trypsin treatment or by
incubation in cold phosphate buffered saline. A certain per-
centage of each sample was used tomeasure luciferase activ-
ity, while the rest of the sample was subjected to a liquid hy-
bridisation protocol. Cells were pelleted, incubated in phos-
phate buffered saline containing 1% NP-40 for 10 min on
ice followed by total RNA extraction according to standard
protocols. The quantification of the siRNA was achieved
by hybridisation with the corresponding 32P-labelled sense
strand for 10min at 95◦C followed by 1 h incubation at 37◦C
before the samples were resolved by 20% polyacrylamide
gel electrophoresis under nondenaturing conditions. After
blotting of the gel onto a nylon membrane (Hybond N+,
Amersham, Freiburg, Germany), the signals were quanti-
fied with a PhosphorImager (TyphoonTM 8600 Variable
Mode Imager, GE Healthcare, Mu¨nchen, Germany). Ab-
solute amounts of siRNA in the samples were calculated
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in relation to the included standards. For this purpose, de-
fined amounts of siRNA were added to control cell lysates
before the extraction step and treated simultaneously with
the other samples. The amounts of total cellular RNA were
determined spectrophotometrically and used for normali-
sation. Supplementary Figure S1 shows the correlation be-
tween the siRNA concentration in the transfection mix
and siRNA molecules taken up intracellularly. Since pre-
vious investigations (49,51–53) have shown that of those
molecules only about 4% of siRNA taken up are bioavail-
able (i.e. available for the RNAimachinery), numbers deter-
mined with the liquid hybridisation assay were multiplied
with a factor of 0.04 to account for this fact.
Quantification of intracellular luciferase mRNA concentra-
tion by quantitative polymerase chain reaction
RNA was extracted from either HTOL or HTO (in this
case, transfected with different amounts (0.1, 1, 10 and
100 ng/well) of pTRE2hyg-luc plasmid by LF2000) cells
(grown in 96-well plates at about 15 000 cells) with Qi-
azol (Qiagen), followed by DNA digestion with TURBO
DNase (Ambion/Life Technologies), phenol/chloroform
and chloroform extractions. After resuspension of the
RNA in water, nucleic acid concentration was deter-
mined with a NanoDrop Instrument (Thermo Scientific).
cDNA synthesis was performed with 1 g of RNA and
200 ng random primers in 20 l reaction volume us-
ing the RevertAid First Strand cDNA Kit (Fermentas).
Real-time-quantitative polymerase chain reaction (qPCR)
was performed in 384-well plates at 10 l each with a
7900HT system (Applied Biosystems) using the Sequence
Detection Systems Software version 2.4 and SYBR Se-
lect Master Mix (Life Technologies). The amplicon size
was 104 nt using the following forward and reverse
primers: 5′-GAACATCACGTACGCGGAATAC and 5′-
TTTCACTGCATACGACGATTCTG, respectively. As an
internal control, mRNA levels of the house keeping
gene GAPDH were determined. Here, the amplicon size
was 86 nucleotides using the following forward and re-
verse primers: 5′-GACAGTCAGCCGCATCTTCTT and
5′-TCCGTTGACTCCGACCTTC, respectively. In case of
HTOL cells, we determined about 1000 copies of GAPDH
mRNA molecules per cell, which nicely fit published num-
bers by others (54–56).
Kinetic modelling of RNAi
In this study, the RNAi process in mammalian cells is for-
mally described by a network of elementary reactions. Their
biochemical rate equations connect experimentally derived
in vitro reaction rate constants with physiological concen-
trations of reactants and cell compartment volumes. The
reaction mechanism is encoded in the reactions’ rate laws,
its parameters (Supplementary Tables S1 and S2) and the
way the reactions are linked to one another in the two alter-
native metabolic pathways (Supplementary Figure S2). The
reactions for the models translate in reaction kinetics equa-
tions as given in Equations 1–16 (Supplementary Equations
1). The difference between the two models is illustrated in
Figure 1. Mathematically, the kinetics of a network of bio-
chemical reactions can be described by a set of ordinary
differential equations (ODEs); Equations 17–29 and 30–45
for the dissociative and the associative model, respectively
(Supplementary Equations 2 and 3). These equations are
solved numerically for time course simulations. Besides time
courses of molecule concentrations, two further parameters
serve as indicators: t1/2 of target knockdown and IC50 of
siRNA. The time of half-maximal target knockdown is de-
scribed by the constant t1/2. It is used as a contracted mea-
sure of time-resolved target knockdown to be able to relate
model behaviour with two free variables simultaneously, i.e.
basal target mRNA level and initial siRNA concentration.
IC50 is defined as the half-maximal inhibitory siRNA con-
centration and indicates howmuch of a particular siRNA is
required for half-maximal reduction of basal target mRNA
level within 24 h. In this study, IC50 is used to compare the
potency of the RNAi machinery at different levels of target
mRNA. Time course simulations, t1/2 and IC50 estimations,
as well as, sensitivity analyses are performed with Copasi
(57) and are described under Supplementary Information.
Model validation
The dissociative model was designed according to the com-
mon literature view on RNAi in mammalian systems and
parameterized according to in vitro determined rate con-
stants (48) and cellular parameters for reactant concentra-
tions (siRNA, hAgo2 and target mRNA) and cytoplasm
volume (Supplementary Table S2). Due to a discrepancy be-
tween the dissociative model and time course data from cell
culture experiments, a second model was developed. The
associative model is based on the fact that recent cell cul-
ture experiments revealed that gene silencing rates can be
increased by raising the target mRNA concentrations, while
the concentrations of siRNA and Ago2 stayed constant.
Likewise, this model was also parameterized according to
the above given rate constants and cellular parameters for
reactant concentrations and reaction compartment volume.
To test whether either of the two models agrees with
RNAi activity in livingmammalian cells, several cell culture
experiments were performed and the validation datasets
were compared with the simulation output of both mod-
els. Essentially, two different sets of validation experiments
were performed: (i) time courses and t1/2 of the siRNA-
mediated knockdown of target gene activity for differ-
ent initial siRNA concentrations, and (ii) concentration
response curves and IC50 determinations of the siRNA-
mediated knockdown of target gene activity at different
basal target mRNA concentrations.
RESULTS
Dissociative model of siRNA-mediated RNAi in mammalian
systems
Acomputationalmodel of siRNA-mediatedRNAi inmam-
malian cells was developed in order to link experimental re-
sults with a quantitative and time-resolved understanding
of RNAi. Mechanistically, it is based on the current litera-
ture view on RNAi. The model is parameterized with pre-
cise quantitative kinetic and molecular data. For each re-
action step, described as elementary reaction equilibrium,
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Figure 1. Illustrations of multiple turnover hAgo2 mRNA cleavage cycle according to the proposed models of RNAi in mammalian cells. Ago2 is repre-
sented as a cartoon deduced from the electron density cloud of X-ray structures with the four domains N, PAZ,Mid and PIWI coloured individually. RNAs
are indicated by lines and colour blue, red or purple for guide, target or product strands. The relative spatial positions of protein and RNA substrates are
indicated and formation of Watson-Crick base pairs is illustrated by short connecting lines between RNA strands. (A) Dissociative model; once a stable
binary complex between ss guide siRNA and Ago2 is formed the system undergoes multiple rounds of target binding, cleavage and product release. (B)
Associative model; in contrast to the dissociative model, here target cleavage is followed by the associative binding of another target, which may invade
the hydrogen bonds between guide and target mRNA cleavage products, eventually replacing the product strands. The cycle is closed by dissociation of
the product fragments, which leads to the formation of the next catalytically active complex. For clarity, only the most relevant steps are shown; a detailed
scheme including all steps of the complex reaction is shown in Supplementary Figure S2. c.a.: catalytically active, p.c.: product complex.
either a pair of forward and backward rate constants, or in
case of quasi-irreversible steps, a forward rate constant is
provided (Supplementary Table S1). The parameters of the
reaction compartment used for computational modelling
(e.g. volume of the cytoplasm of a mammalian cell and con-
centrations of reactants) are provided in Supplementary Ta-
ble S2. In order to take into account transcriptional bursts,
which are frequently observed for mRNA in mammalian
cells (58), occasional high target RNA concentrations could
be assumed. Nevertheless, to not needlessly complicate the
system, a setup with assumed constant mRNA concentra-
tion was chosen, i.e. constant mRNA synthesis and elim-
ination rates (Supplementary Table S2). The name, disso-
ciative model, is based on the biochemical ligand substitu-
tion mechanism it resembles. In the dissociative model, the
departing ligand (here, cleaved RNA fragments) leaves the
complex in a slow step with positive entropy of activation,
before the incoming ligand (target mRNA) can enter (Fig-
ure 1A).
In a first pass, hAgo2 and possibly other cofactors, bind
free ss guide siRNA (below referred to as guide) in a three-
step reaction to form a binary Ago2/guide substrate com-
plex (siRNA binding I-III). The entire reaction pathway
is illustrated in Supplementary Figure S2. Corresponding
rate equations and rate constants for each individual step
are listed under Supplementary Information (Supplemen-
tary Equations 1) and given in Supplementary Table S1,
respectively. Potential cofactors, passenger strand cleavage
and release during binary complex formation are left out
for clarity but essentially, the proposed pathway also holds
true for ds siRNA. Next, a target RNA enters the binary
Ago2/guide complex and, if complementary to the bound
guide RNA, associates in a three-phase reaction, to form
a catalytically active ternary Ago2/guide/target RNA sub-
strate complex (target binding I-III). Once a catalytically
active complex is formed, the system can undergo multiple
rounds of target binding and cleavage, each time followed
by a slow product release, without the binary Ago2/guide
complex falling apart. The bound target mRNA is cleaved
by Ago2 (target cleavage reaction) leading to a ternary
Ago2/guide/product complex. Subsequently, the cleavage
product is released from the complex in a three-step reaction
(product dissociation I-III). Accordingly, the target mRNA
population is reduced by one and released product strands
are prone to degradation by cellular nucleases, leaving be-
hind a binary complex comprising guide bound to Ago2,
which can bind another target mRNA and thus closing the
cycle of subsequent passes of target turnover.
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Figure 2. Dependency of observed rate of target knockdown on siRNA
and target mRNA concentration. (A) t 1
2
, the time of half-maximal tar-
get knockdown, is plotted against logarithmically-scaled initial siRNA
concentration and logarithmically-scaled basal target concentration. t 1
2
of dissociative and associative model span the blue and the black surface
over the parameter space, respectively. (B) It shows a cross-section of the
3D-plot at a basal target concentration of 35 copies/cell (experimentally
determined luciferase mRNA copy number in stably transfected HTOL
cells). For decreasing siRNA concentrations, the difference in t 1
2
between
the dissociative (blue line) and the associative (black line) model increases
progressively. Experimentally determined t 1
2
values of knockdown of lu-
ciferase reporter gene activity after LF2000-mediated transfection of dif-
ferent amounts of siR206 into HTOL cells are depicted by red squares.
Transfection of 0.05, 0.1, 0.5, 1, 50 and 100 nM siRNA in the transfection
mix translates into 31, 63, 314, 628, 5261 and 10 523 copies of bioavailable
siR206 per cell (Supplementary Figure S1). For details see Materials and
Methods and references (49,53). The corresponding t1/2 values are: 19 (±
2.5), 10.6 (± 2.4), 6.7 (± 0.3), 5.6 (± 0.4), 3.5 (± 0.2) and 2.9 (± 0.25) h (for
experimental details see Supplementary Figure S7). The data are an aver-
age of at least two independent experiments. The inset shows the graph on
a shorter y-axis scale including corresponding error bars.
RNAi in mammalian cells suggests an alternative model
structure
In a first attempt to test themodel’s relevance inmammalian
cells, time-course simulations of mRNA target knockdown
were compared to cell culture experiments (Figure 2). As
a cellular model system, we used the HTOL cell line, stably
transfectedwith a firefly luciferase reporter construct as pre-
viously described (49). For reporter knockdown, different
amounts of an antiluciferase siRNA, namely siR206 (50),
were transfected with LipofectamineTM 2000 (LF2000). Lu-
ciferase mRNA levels were determined by qPCR as de-
scribed under Materials and Methods. For quantification
of the amount of siRNA internalized, a so-called liquid hy-
bridisation assay enabling us to detect the guide strand of
the siRNA with a sensitivity of >10 molecules per cell was
applied as described previously (49). In Figure 2A, t 1
2
spans
the surface of the parameter space of two initial concen-
trations, siRNA [S]0 and target [T]0. In general, t 1
2
is pro-
portional to [T]0 and antiproportional to [S]0. It is also ev-
ident that t 1
2
is very sensitive to changes in [S]0 while also
being sensitive to changes in [T]0. Figure 2B shows a cross-
section of the 3D-plot in 2A, at a basal target concentra-
tion of 35 copies per cell, which corresponds to the average
basal targetmRNAconcentration in the control experiment
(i.e. copy number of luciferase mRNA in stably transfected
HTOL cells). A first discrepancy between the dissociative
model and experimentally determined values (red squares)
was observed. It was not possible to eliminate the discrep-
ancy between the model and experiment by merely adjust-
ing the model parameters within physiological meaningful
boundaries. For example, a 20-fold increase of themeasured
in vitro constants of the two most sensitive parameters (i.e.
product release III k+10 and target binding III k+6; compare
Supplementary Information on sensitivity analysis, Supple-
mentary Figure S6 and Supplementary Table S1), which
may be justified by facilitating cofactors in vivo,was not suf-
ficient to solve the discrepancy.
Associative model: accelerated product release possibly via
strand exchange between Ago2-bound cleaved target RNA
and next incoming target mRNA
Cell culture experiments revealed that despite rising tar-
get mRNA concentrations over several orders of magni-
tude, gene knock-down efficiency, given as half-maximal
inhibitory siRNA concentration (IC50) 24 h post transfec-
tion, stayed constant (compare Figure 4). Thus, in order
to compensate for the increase in target mRNA cleavage,
the RNAi machinery must become more effective. Along
these lines, transient in vitro binding experiments showed
that the release of a target or product RNA strand from
a ternary hAgo2/guide/target or product complex is ac-
celerated in the presence of an excess of the next incom-
ing target RNA (48) (Supplementary Figure S3). Taken to-
gether, these two experimental findings imply that RNAi-
mediated gene knockdown is capable to adapt to large
changes in target mRNA level without affecting efficacy by
target-induced acceleration of the overall rate-limiting step,
namely release of cleavage products. The lack of the above
described dissociative model to account for such a scenario
motivates the development of an alternative so-called asso-
ciative model.
Different from the dissociative mechanism, the associa-
tive model involves the association of an incoming ligand
with the enzyme/substrate complex before departure of
the leaving ligand. In this model, hAgo2 supposedly facil-
itates the interaction of an incoming target strand with a
ternary hAgo2/guide/product complex, most likely by a
kind of strand invasion mechanism as proposed for in vitro
RNA/RNA strand exchange (59,60). As shown in Supple-
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mentary Figures S9 and S10, such interactions only take
place in case of fully complementary targets. Figure 1B pic-
tures the target-product-exchangemechanism, which is fun-
damental to the multiple turnover cycle of the associative
model.
The first passes of siRNA binding, followed by target
binding, as well as, target cleavage are equivalent to the re-
action steps of the dissociative mode: ‘siRNA binding I-
III’, ‘target binding I-III’ and ‘target cleavage’, respectively.
However, after target mRNA cleavage and formation of the
hAgo2/guide/product complex, the two models differ. In
contrast to the dissociative model, target cleavage is fol-
lowed by an associative binding of another target (asso-
ciative target binding I-III). A newly incoming target inter-
acts with the ternary hAgo2/guide/product complex, form-
ing a transient quaternary complex eventually replacing the
product. The cycle is closed by the complete release of the
product in three reaction steps (product release I-III), lead-
ing to the formation of the next catalytically active ternary
complex. Like in the dissociative model, released product
fragments are subsequently degraded by cellular nucleases.
The remaining ternary complex can pass through the next
cycle of target cleavage, association of a new target and
product release. The full reaction scheme for the associative
model is shown in Supplementary Figure S2B. Analogous
to the dissociativemodel, the rate constants for complex for-
mation and dissociation are based on presteady state bind-
ing data (Supplementary Table S1) by Deerberg et al. (48).
The associative model closely resembles siRNA-mediated tar-
get knockdown in cell culture
As described above, time-course simulations were repeated
with the associative model (Figure 2A) and t 1
2
of target
knockdown was likewise compared to experimental data.
For a combination of high siRNA0 and low target0 concen-
trations, surfaces of both models superimpose well. How-
ever, they increasingly diverge with higher target0 concen-
tration and to a lesser extend with lower siRNA0 concen-
tration. Experimentally determined t 1
2
values (red squares
in Figure 2B), more closely match the behaviour of the as-
sociative model.
Time-resolved target knockdown with respect to initial
siRNA concentration
After administration of siRNA, target mRNA concentra-
tion and as a consequence gene activity decrease within a
defined time span until reaching a minimum. In cell cul-
ture, recovery of mRNA concentration back to basal lev-
els takes 2–5 days and is likely to be controlled by dilu-
tion of siRNA or loaded RISC due to cell division (36). In
this work, the time-resolved knockdown of target mRNA
concentration as a function of administered siRNA dose
as well as of basal mRNA level was analysed on a short-
term time scale of 6 h (Figure 3). hAgo2 concentration was
set to 200 000 copies/cell (61) and did not limit model per-
formance down to 10 000 or 50 000 copies/cell for neither
the associative or dissociative model (Supplementary Fig-
ure S4). Thus, initial hAgo2 concentration was not of con-
cern during the simulations performed, where a number of
time course simulations with different combinations of ad-
ministered siRNA dose and basal mRNA level were calcu-
lated for both models. Figure 3 shows the time-resolved on-
set of target knockdown within the first 6 h after siRNA
administration as a function of initial siRNA concentra-
tion, where relative target concentration is given as func-
tion of reaction time and initial siRNA concentration. At
lower target levels (i.e. 10 copies/cell), the RNAi machinery
according to both models, respond likewise to changes in
siRNA concentration of several orders of magnitudes (Fig-
ure 3A/B). However, in case of the dissociative model, the
RNAi machinery requires increased siRNA concentrations
to maintain the rate of target knockdown at higher target
levels, i.e. 100 copies/cell (Figure 3C/D). In contrast, for the
associative model, the relative time courses of target knock-
down are far more similar for different levels of basal target
concentrations. This difference, in time-dependent model
behaviour between dissociative and associative model, be-
comes more recognizable at even higher target levels of
≥1000 copies/cell (Figure 3E/F). Supplementary Figure S8
shows a direct comparison between experimentally deter-
mined and simulated data at concentrations where the dif-
ference among the two models is most significant; i.e. high
target and moderate siRNA concentrations.
Messenger RNA synthesis may be triggered by transcrip-
tional bursts (58) and mRNA levels in mammalian cells
can vary by magnitudes between 1–10 000 copies/cell (62).
Thus, RNAi-mediated knockdown should be able to adapt
to such massive changes in target mRNA levels, as reflected
by the proposed associative, but not the dissociative model.
Adaptation of the RNAi machinery to variations in target
mRNA level indicated by IC50 values
To further investigate the adaptiveness of the RNAi ma-
chinery to changes in target mRNA levels, calculated IC50
values (given as siRNA copies/cell) were plotted against
basal target mRNA levels (Figure 4). The simulated val-
ues were then compared to experimentally determined num-
bers. The experimentally derived IC50 values are essentially
constant over four magnitudes of LF2000 transfected tar-
get pTREhyg-luc plasmid intoHTO cells (0.1–100 ng/well),
which translates into 0.5–715 luciferase mRNA copies/cell,
as determined by qPCR. This indicates a robustness of the
RNAi machinery against a certain extend of variation in
target mRNA levels. For the dissociative model, the IC50
stays relatively constant for small target concentrations of
<50 copies/cell, and then increases rapidly. In the associa-
tive model, the IC50 slowly decreases with increasing tar-
get concentration until it reaches its optimum between 200
and 300 target copies/cell from where the IC50 starts in-
creasing with the target copy number. All in all, the as-
sociative model describes the observed adaption to varia-
tions in target mRNA level much more convincing than
the dissociative model. Figure 5 shows the difference be-
tween the two models by plotting IC50 ratios (quotient
IC50 diss/IC50 ass) versus target copies per cell. Here, the
effect is most obvious for the physiologically significant
range of 50–10 000 mRNA copies/cell.
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Figure 3. Time resolved siRNA-mediated target knockdown with respect to initial siRNA concentration at three different levels of basal target mRNA.
In all six plots, target concentration (in percent of basal target level) is plotted against reaction time (in h) and logarithmically-scaled initial siRNA
concentration (in copies/cell). Simulation results of the dissociative model in the first column are presented in parallel with the ones of the associative
model in the second column. Row-wise, absolute basal target levels increase by 10-fold from 10 to 100 to 1000 copies/cell.
DISCUSSION
Precise kinetic data made it possible to model siRNA-
mediated RNAi with never observed precision. Our exper-
imental observations suggest high multiple turnover rates
of RNAi-based gene silencing in cell tissue culture and sta-
bility of gene silencing efficacy over several magnitudes of
targetmRNAconcentration. That is, gene silencing rates in-
creasewhen targetmRNAconcentration rises, while siRNA
concentration stays constant.
First modelling approaches (later dubbed dissociative
model) were not consistent with experimental data derived
from tissue culture. Sensitivity analyses (Supplementary
Figure S6) revealed product release step III (k+10; see Sup-
plementary Figure S2A) as the limiting step for mRNA tar-
get knockdown in this model explaining the discrepancy to
the experimental findings. In contrast, the cell culture data
can be sufficiently described by an associative model using
measured model parameters. Here, product release (k+16;
see Supplementary Figure S2B) is not limiting (Supplemen-
tary Figure S6). The associative model accounts for target
concentration-dependent acceleration of product release
from Ago2 and is compatible with a high multiple turnover
rate of RNAi-based gene silencing in tissue culture. Thus,
we propose an associative mechanism of mRNA target
binding and recognition by the postcleavage guide/product
duplex, facilitated by hAgo2 during the catalytic cycle. Such
a scenario is supported by data from Wu¨nsche et al. (60),
which quantified increased RNA/RNA association kinet-
ics during strand exchange between siRNA duplexes and
corresponding target RNA strands in vitro.
Comparison between simulated and experimentally de-
termined IC50 values suggests that the associative mech-
anism interlinks target mRNA loading with acceleration
of unloading of cleaved product fragments from Ago2 un-
der multiple turnover conditions in a target concentration-
dependent fashion. Our findings are supported by observa-
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Figure 4. Dependency of RNAi efficacy on target mRNA concentration.
For both models (dissociative: blue line; associative: black line), simu-
lated IC50 values (specified as copies/cell; conversion given under Mate-
rials and Methods) are plotted against logarithmically-scaled basal target
mRNA concentration. Experimentally determined IC50 values of siR206
are shown by red dots. Here, siR206 (0.0005, 0.005, 0.05, 0.5, 5 and 50 nM)
and pTRE2hyg-luc plasmid (0.1, 1, 10 and 100 ng/well) were cotransfected
into HTO cells. In the absence of siRNA 0.5 (±0.1), 3.2 (±0.3), 58 (±2),
and 715 (±23) luciferase mRNA copies/cell were determined by qPCR for
the different amounts of plasmid transfected. For each concentration of
pTRE2hyg-luc plasmid, IC50 values were determined by plotting qPCR-
derived mRNA copy numbers versus concentrations of transfected siR206
yielding the following values: 0.1 ng plasmid/well = IC50 19 (±8), 1 ng
plasmid/well= IC50 19 (±5), 10 ng plasmid/well= IC50 15 (±11) and 100
ng plasmid/well = IC50 10 (±2) copies/cell. Standard deviations are given
by horizontal and vertical error bars.
Figure 5. Quotient IC50 diss/IC50 ass as function of initial target mRNA.
The simulated IC50 values for the dissociativemodel divided by IC50 values
for the associative model are plotted against logarithmically-scaled basal
target mRNA concentration.
tions of other groups. Already in 2003, Harborth et al. (63)
detected differences in siRNA-dependent silencing efficien-
cies targeting sequence segments identical among human
and mouse lamin A/C. They assumed that among others
the different levels of target mRNA in human and mouse
cells might account for different silencing efficiencies. An-
other study showed that transcripts with low abundancy are
less susceptible to siRNA-dependent Ago-mediated cleav-
age suggesting the necessity of a certain target transcript
threshold for efficient gene silencing (64). In contrast to
these conceptions, Krueger et al. (65) excluded a correla-
tion between transcript levels and gene silencing efficien-
cies in their studies using a random set of validated siR-
NAs. This discrepancy could possibly be explained by find-
ings demonstrating that the effect of target transcript abun-
dance is relativized if the turnover rates of the target are very
high or the siRNA used is very efficient (40). But since it
could be shown that transcripts with the highest abundance
are usually correlated with low turnover numbers (40), the
importance of target transcript levels for efficient siRNA-
mediated RNAi is underscored. Interestingly, the correla-
tion between target RNA abundance and gene silencing ef-
ficiency seems to be restricted to siRNA-dependent RNAi.
Analyses of a possible connection between transcript abun-
dance and miRNA-dependent gene silencing revealed simi-
lar gene silencing efficiencies for lowly and highly expressed
target transcripts (66). These results might be correlated
with the fact that in case of miRNAs, which are not fully
paired to their targets, dissociation rate constants of ternary
Ago/guide/target complexes are faster than in case of their
nearly fully paired siRNA counterparts (67), and therefore,
may not limit Ago-mediated target turnover.
Questions like ‘what determines the cellular response to
a siRNA or miRNA stimulus?” and ‘how to quantitatively
predict it?’ are sought after for improved and secure ap-
plication of RNAi in medicine and life science. It is com-
monly accepted that factors like local RNA sequence con-
text (68) or structure (69–72) are important for RNAi effi-
ciency. However, inconsistencies in state-of-the-art siRNA
design and prediction of RNAi efficacy hint that limitations
may not be solely in the design of the siRNA molecule it-
self. In fact, it was shown that system-level properties such
as RNA elimination rates have important, but still incon-
clusive effects on RNAi efficacy (40). Likewise, our study
strongly suggests considering the target as a whole when
choosing appropriate targets or when predicting gene si-
lencing efficacy. This implies the need of a new generation of
bioinformatics tools for siRNA (andmiRNA) target predic-
tion, which consider system-level properties such as target
transcript abundance and mRNA decay rates. For instance,
anmRNA in one cell typemay not be targetable to the same
extent in another cell type, depending on the abundance of
the mRNA.
Transcriptional bursts and the resulting variability in
mRNA abundance (i.e. transcriptional noise) among iso-
genic cell populations impact upon the effectiveness of
clinical treatment and the resistance of bacteria to antibi-
otics (73,74). Variability in gene expression may also con-
tribute to resistance of subpopulations of cancer cells to
chemotherapy (75). Robustness of RNAi drugs to tran-
scriptional bursts as shown in our IC50 experiments and
the here proposed associative model, may be an important
property of RNAi-based drugs to overcome microbial and
cancer cell resistance to conventional drugs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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